• Yoji Ishizu, Masatoshi Ishigami, Takashi Honda, Norihiro Imai, Takanori Ito, Kenta Yamamoto, Shinya Yokoyama, Tetsuya Ishikawa, and Mitsuhiro Fujishiro.
• Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: y-ishizu@med.nagoya-u.ac.j.
• Nutrition. 2022 Nov 1; 103-104: 111777.

ObjectivesThe presence of myosteatosis is one factor associated with poor prognosis for patients with cirrhosis; however, the factors contributing to worsening myosteatosis are, to our knowledge, unknown. The aim of this study was to clarify the changes in myosteatosis, and the factors involved in these changes.MethodsThe present study enrolled 178 patients with cirrhosis who underwent computed tomography twice to measure changes in skeletal muscle attenuation (SMA) at the L3 level. Factors associated with SMA and those associated with changes in SMA were examined.ResultsUsing linear multiple regression analysis, age (β = -0.22), skeletal muscle index (SMI; skeletal muscle area divided by height squared; β = 0.25), and visceral and subcutaneous fat indices (VFI and SFI; the visceral and subcutaneous fat areas at the umbilical level divided by height squared; β = -0.08, β = -0.06, respectively) were identified as associated with SMA. The 100-d change in SMA was -0.21 ± 1.29 Hounsfield units (HU). Changes in SMI and SMA were positively associated (R = 0.183, P = 0.014), whereas those in VFI and SMA were negatively associated (R = -0.172, P = 0.022). No association was noted between the 100-d changes in SFI and SMA. In patients whose SMI increased and VFI decreased, the 100-d change in SMA was 0.24 ± 1.82 HU, which was marginally different from that in patients whose SMI decreased and VFI increased (-0.44 ± 1.32 HU, P = 0.077).ConclusionsIn patients with cirrhosis, myosteatosis progressed, and decreases in SMI and increases in VFI were correlated with its progression.Copyright © 2022 Elsevier Inc. All rights reserved.

16 keywords...

hide…